Physician profile
Samuel E Friedman
NPI 1265480495
$748.04
in general payments reported to CMS, 2019-2025
12 companies · $121 in 2025
The $121 reported for 2025 was more than what a typical Diagnostic Radiology provider received nationally (typical 2025 total: $112).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $529 · 2020: $28.49 · 2022: $23.99 · 2024: $45.40 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $166.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sirtex Medical INC | $148.78 | 2019 | |
| Merck Sharp & Dohme LLC | $120.89 | 2025 | |
| Novartis Pharmaceuticals Corporation | $120.57 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $101.30 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $72.19 | 2019-2024 | |
| Amgen INC. | $51.66 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $35.24 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $32.39 | 2019 | |
| Abbvie INC. | $24.38 | 2019 | |
| Clovis Oncology, INC. | $14.89 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.77 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.